Neumora Therapeutics (NMRA) Other Non-Current Assets (2022 - 2025)
Neumora Therapeutics (NMRA) posted quarterly Other Non-Current Assets of $53000.0 for Q4 2025, down 95.63% year-over-year from $1.2 million in Q4 2024, and down 82.21% quarter-over-quarter from $298000.0 in Q2 2025.
Neumora Therapeutics (NMRA) Other Non-Current Assets (2022 - 2025) Analysis & Trends
Neumora Therapeutics' Other Non-Current Assets history runs 4 years deep, the most recent figure standing at $53000.0 for Q4 2025.
- In Q4 2025, Other Non-Current Assets fell 95.63% year-over-year to $53000.0; the TTM figure through Dec 2025 stood at $53000.0 (down 95.63% YoY), while the FY2025 annual figure was $53000.0, down 95.63% from the prior year.
- Other Non-Current Assets for Q4 2025 stood at $53000.0, down from $298000.0 in the prior quarter.
- The five-year high for Other Non-Current Assets was $1.3 million in Q4 2022, with the low at $53000.0 in Q4 2025.
- The 4-year median for Other Non-Current Assets is $1.2 million (2023), against an average of $1.1 million.
- The sharpest annual moves came in 2024 and 2025: Other Non-Current Assets changed 0.0% in 2024, then sank 95.63% in 2025.
- Neumora Therapeutics' Other Non-Current Assets stood at $1.3 million in 2022, then fell by 3.96% to $1.2 million in 2023, then changed by 0.0% to $1.2 million in 2024, then tumbled by 95.63% to $53000.0 in 2025.
- Business Quant data shows NMRA's Other Non-Current Assets at $53000.0 in Q4 2025, $298000.0 in Q2 2025, and $1.2 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Neumora Therapeutics | 296.45 Mn | 296.45 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 53,000.00 |
| Jun 30, 2025 | 298,000.00 |
| Mar 31, 2025 | 1.21 Mn |
| Dec 31, 2024 | 1.21 Mn |
| Sep 30, 2024 | 1.21 Mn |
| Jun 30, 2024 | 1.21 Mn |
| Mar 31, 2024 | 1.21 Mn |
| Dec 31, 2023 | 1.21 Mn |
| Sep 30, 2023 | 1.21 Mn |
| Jun 30, 2023 | 1.21 Mn |
| Mar 31, 2023 | 1.21 Mn |
| Dec 31, 2022 | 1.26 Mn |
| Sep 30, 2022 | 1.26 Mn |